PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells

PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells

As a therapeutic approach, epigenetic modifiers have the potential to enhance the efficacy of chemotherapeutic agents. Protein arginine methyltransferase 5 (PRMT5), highly expressed in lung adenocarcinoma, was identified to be involved in tumorigenesis. In the current study, we examined the potentia...

Full description

Bibliographic Details
Main Authors: Khuloud Bajbouj, Rakhee K. Ramakrishnan, Maha Saber-Ayad, Hany A. Omar, Narjes Saheb Sharif-Askari, Jasmin Shafarin, Adel B. Elmoselhi, Ahmed Ihmaid, Suhib AlHaj Ali, Abdulla Alalool, Reem Abdullah, Qutayba Hamid
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:International Journal of Molecular Sciences
Subjects:
PRMT5
lung cancer
epigenetics
cisplatin
histone
HBEpC
Online Access:https://www.mdpi.com/1422-0067/22/11/6131

Internet

https://www.mdpi.com/1422-0067/22/11/6131

Similar Items